SGLT2 inhibitors: risk of diabetic ketoacidosis

Patients receiving SGLT2 inhibitors (canagliflozin, dapagliflozin or empaglifozin) should be monitored for diabetic ketoacidosis, the MHRA has advised.

Prescribers are reminded that SGLT2 inhibitors are not licensed for the treatment of type I diabetes.
Prescribers are reminded that SGLT2 inhibitors are not licensed for the treatment of type I diabetes.

Serious and life-threatening cases of diabetic ketoacidosis have been reported in patients taking SGLT2 inhibitors. In several cases, blood glucose levels were only moderately elevated (eg, <14 mmol/L or 250mg/dL), which is atypical for diabetic ketoacidosis. 

The MHRA has issued the following recommendations for prescribers:

  • Test for raised ketones in patients with symptoms of diabetic ketoacidosis, even if plasma glucose levels are near-normal. 
  • Discontinue treatment if diabetic ketoacidosis is suspected. 
  • If diabetic ketoacidosis is confirmed, take appropriate corrective measures and monitor glucose levels.
  • Continue to report suspected side-effects of SGLT2 inhibitors.

Further information
MHRA Drug Safety Update 
View SGLT2 inhibitor drug records

To avoid a delay in diagnosis and treatment of diabetic ketoacidosis, prescribers should inform patients of the symptoms and signs:

  • nausea
  • vomiting
  • anorexia
  • abdominal pain
  • excessive thirst
  • difficulty breathing
  • confusion
  • unusual fatigue or sleepiness.
Prescribers are reminded that SGLT2 inhibitors are not approved for the treatment of type I diabetes. 
Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

MIMS publishes summary of new NICE diabetes guidance

MIMS publishes summary of new NICE diabetes guidance

A quick-reference MIMS summary of the recently revised...

NICE approval for newest SGLT2 inhibitor in diabetes

NICE approval for newest SGLT2 inhibitor in diabetes

Patients with type II diabetes will be able to get...

Vokanamet: new combination oral hypoglycaemic

Vokanamet: new combination oral hypoglycaemic

Janssen-Cilag has launched a twice-daily fixed dose...

Jardiance: further SGLT2 inhibitor option available

Jardiance: further SGLT2 inhibitor option available

Boehringer Ingelheim has launched Jardiance (empagliflozin),...

Canagliflozin approved by NICE for diabetes

Canagliflozin approved by NICE for diabetes

NICE has approved canagliflozin (Invokana) for use...

Xigduo (dapagliflozin + metformin): first SGLT2 inhibitor combination tablet

Xigduo (dapagliflozin + metformin): first SGLT2 inhibitor combination tablet

Xigduo (dapagliflozin + metformin) has been launched...

Invokana: new SGLT2 inhibitor for type II diabetes

Invokana: new SGLT2 inhibitor for type II diabetes

Janssen-Cilag has launched Invokana (canagliflozin)...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases